Effects and mechanism study of PCSK9 inhibitor on cardiac function in patients with ultra-high-risk coronary atherosclerosis: A Study Protocol for a Randomized controlled protocol

Effects and mechanism study of PCSK9 inhibitor on cardiac function in patients with ultra-high-risk coronary atherosclerosis: A Study Protocol for a Randomized controlled protocol

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300071501

Enrollment

Unknown

Registered

2023-05-17

Start date

2022-11-03

Completion date

Unknown

Last updated

2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerotic cardiovascular disease

Interventions

Experimental group:application of PCSK9 inhibitors

Control group:statins alone or in combination with ezetimibe

Sponsors

the Second Hospital of Tianjin Medical University

Lead Sponsor

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-80 years old; 2. After undergoing coronary angiography/PCI; 3. Ultra high risk coronary Atherosclerosis patients with fasting LDL-C>3.0 mmol/L.

Exclusion criteria

Exclusion criteria: 1) patients with allergies to the study drug; 2) pregnancy and malignancy; 3) patients with congenital heart disease, severe heart valve disease, cardiomyopathy and other heart diseases; 4) patients requiring surgery.

Design outcomes

Primary

Measure	Time frame
LDL-C;Major adverse cardiac events;	—

Secondary

Measure	Time frame
all cause mortality;	—

Countries

China

Contacts

Public ContactHuaying Fu

the Second Hospital of Tianjin Medical University

huayingfu@tmu.edu.cn+86 138 2040 6212

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026